AMENDMENT NO. 2 TO THE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 14th, 2023 • Decibel Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER 2 (“Amendment No. 2”), dated as of February 6, 2023 (the “Amendment No. 2 Effective Date”), is by and between REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”), and DECIBEL THERAPEUTICS, INC., a corporation organized under the laws of Delaware and having a place of business at 1325 Boylston Street, Suite 500, Boston, MA 02215 (“Decibel”) (with each of Regeneron and Decibel referred to herein individually as a “Party” and collectively as the “Parties”), and amends the License and Collaboration Agreement by and between Decibel and Regeneron, dated as of November 15, 2017 (the “Agreement”), as previously amended by Amendment Number 1 (“Amendment No.1”) thereto dated as of October 5, 2020 and modified by the Designation of Decibel Additional Targets dated as of January 12, 2018 and by Regeneron’s election in accordance with
